These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9581866)

  • 21. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
    Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
    Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW
    Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
    Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
    Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
    Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
    Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
    Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.